NYESO-TCR

European patent · EP3555124 · In force

Register entry

Publication number
EP3555124
Application number
EP19703958
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jan 28, 2019
Published
Oct 23, 2019
Granted
May 1, 2024
Protection ends at the latest
Jan 27, 2039
Next annual fee due
Jan 31, 2027
IPC classes
C07K 16/30 (2006.01)
C07K 14/725 (2006.01)
C07K 16/28 (2006.01)
Priority
LU 100715 26.02.2018
PCT application
PCT/EP2019/051963 28.01.2019
PCT publication
WO2019/162043 29.08.2019
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Feb 17, 2026

    Change

    Published in Swissreg on 17.02.2026

  2. Mar 12, 2025

    Change

    Published in Swissreg on 12.03.2025

  3. Feb 1, 2025

    Change

    Published in Swissreg on 01.02.2025

  4. Jun 14, 2024

    Agent entered

    Representative
    VALIPAT, c/o BOVARD LTD, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 14.06.2024

  5. May 1, 2024

    Granted

    Published in Swissreg on 01.05.2024

Parties

Holder

Medigene Immunotherapies GmbH

Lochhamer Straße 11, 82152 Planegg-Martinsried, DE

Agent

VALIPAT c/o BOVARD LTD

Optingenstrasse 16, 3013 Bern

Inventor

WEHNER, Carina

80809 Munich, DE

WEIS, Manon

80802 Munich, DE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.